Biogen Inc (BIIB)

[growacet]

Obviously there's a HUGE value for an AD treatment....

That $16 billion hit the Mcap took here shows how much value the market places on even a potential treatment for Alzehimer's disease.

There's a Phase 3 trial going on by a Canadian Biotech that's very much below the radar, and cognition is one of the secondary endpoints that they're measuring on patients over 70 years of age, many of whom have MOCA scores below 25, indicative of cognitive impairment.

This is a SA blog post about them which mentions Biogen and failed AD drug Aducanumab.

https://seekingalpha.com/instablog/15663412-joe_retail/5302150-resverlogix-keeps-climbing-high-can-go